Myriad Genetics Inc
MYGNStock
$6.19+26.20%52W
Market Cap$597.86M
P/E—
Div yield—
Beta1.62
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-14.29%
Price vs S&P 500 (4W)47.87%
VGM Score58.56
Market Capitalization$597.86M
Earnings Surprise History
Q1 26-0.09est. -0.07
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.67
2.59
2.63
2.60
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MYGNMyriad Genetics Inc | C | C | B | $6.19 |
| IDXXIdexx Laboratories Inc | D | B | C | $576.07 |
| LNTHLantheus Holdings, Inc | C | B | B | $105.11 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $35.40 |
| NEOGNeogen Corp | C | C | B | $10.33 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $11.86 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | F | $9.60 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | $18.24 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.96 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.32 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | B | $4.71 |
About
Myriad Genetics develops and commercializes molecular diagnostic tests that assess disease risk and guide treatment decisions across medical specialties. The company's portfolio includes BRACAnalysis CDx, GeneSight, MyChoice CDx, Prolaris, and other proprietary tests used to support earlier detection and precision treatment. Revenue is primarily generated in the United States with international operations.